DK0682528T3 - Lægemiddelpræparat til topisk administration af antigener og/eller vacciner til pattedyr via en slimhindemembran - Google Patents

Lægemiddelpræparat til topisk administration af antigener og/eller vacciner til pattedyr via en slimhindemembran

Info

Publication number
DK0682528T3
DK0682528T3 DK94907503T DK94907503T DK0682528T3 DK 0682528 T3 DK0682528 T3 DK 0682528T3 DK 94907503 T DK94907503 T DK 94907503T DK 94907503 T DK94907503 T DK 94907503T DK 0682528 T3 DK0682528 T3 DK 0682528T3
Authority
DK
Denmark
Prior art keywords
pct
antigens
topical administration
drug preparation
mucosal membrane
Prior art date
Application number
DK94907503T
Other languages
English (en)
Inventor
Sveinbjoern Gizurarson
Iver Heron
Original Assignee
Lyfjathroun H F
Statens Seruminstitut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lyfjathroun H F, Statens Seruminstitut filed Critical Lyfjathroun H F
Application granted granted Critical
Publication of DK0682528T3 publication Critical patent/DK0682528T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK94907503T 1993-02-15 1994-02-14 Lægemiddelpræparat til topisk administration af antigener og/eller vacciner til pattedyr via en slimhindemembran DK0682528T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK93170A DK17093D0 (da) 1993-02-15 1993-02-15 Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder
PCT/DK1994/000062 WO1994017827A1 (en) 1993-02-15 1994-02-14 A pharmaceutical preparation for topical administration of antigens and/or vaccines to mammals via a mucosal membrane

Publications (1)

Publication Number Publication Date
DK0682528T3 true DK0682528T3 (da) 2000-12-27

Family

ID=8090567

Family Applications (2)

Application Number Title Priority Date Filing Date
DK93170A DK17093D0 (da) 1993-02-15 1993-02-15 Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder
DK94907503T DK0682528T3 (da) 1993-02-15 1994-02-14 Lægemiddelpræparat til topisk administration af antigener og/eller vacciner til pattedyr via en slimhindemembran

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK93170A DK17093D0 (da) 1993-02-15 1993-02-15 Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder

Country Status (14)

Country Link
US (1) US5942237A (da)
EP (1) EP0682528B1 (da)
JP (1) JPH09508614A (da)
AT (1) ATE195077T1 (da)
AU (1) AU668290B2 (da)
CA (1) CA2156084A1 (da)
DE (1) DE69425427T2 (da)
DK (2) DK17093D0 (da)
ES (1) ES2150982T3 (da)
GR (1) GR3034727T3 (da)
NO (1) NO312057B1 (da)
OA (1) OA10564A (da)
PT (1) PT682528E (da)
WO (1) WO1994017827A1 (da)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9316745D0 (en) 1993-08-12 1993-09-29 Medeva Holdings Bv Vaccine compositions
ES2185900T3 (es) * 1996-01-25 2003-05-01 Profylakse Aps Composicion farmacologica que comprende un componente p serico del amiloide para el tratamiento profilactico o terapeutico de infecciones viricas y un hit para la deteccion de union entre dicha composicion y componentes viricos.
IS4518A (is) * 1997-07-09 1999-01-10 Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group Nýtt lyfjaform fyrir bóluefni
JP2002511423A (ja) * 1998-04-09 2002-04-16 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ワクチン
US7229621B2 (en) * 1998-10-20 2007-06-12 Torrey Pines Institute For Molecular Studies Method to enhance the immunogenicity of an antigen
SE9900495D0 (sv) 1999-02-12 1999-02-12 Pharmatrix Ab Vaccine composition
EP1034792A1 (en) * 1999-03-11 2000-09-13 Pasteur Merieux Serums Et Vaccins Intranasal delivery of pneumococcal polysaccharide vaccines
HUP0202846A3 (en) * 1999-09-24 2003-12-29 Smithkline Beecham Biolog Intranasal influenza virus vaccine
GB9924351D0 (en) 1999-10-14 1999-12-15 Brennan Frank Immunomodulation methods and compositions
AU2002367976B2 (en) * 2001-06-05 2007-06-21 The Regents Of The University Of Michigan Nanoemulsion vaccines
CA2457595A1 (en) * 2001-08-16 2003-02-27 Lyfjathroun H.F., Biopharmaceuticals A method of producing antibodies ex-vivo
KR100406503B1 (ko) * 2001-09-25 2003-11-19 한국과학기술연구원 폐렴구균성 표면 접착단백질의 가용화용 조성물, 가용화용액상제형, 및 가용화용 분말제형, 이들 각각의 제조방법및 백신
AU2003215885B2 (en) * 2002-02-25 2008-07-03 Lyfjathroun Hf Absorption enhancing agent
US6855332B2 (en) * 2002-07-03 2005-02-15 Lyfjathroun Hf. Absorption promoting agent
WO2004047778A1 (en) 2002-11-26 2004-06-10 Uc Tech Materials and methods for preventing and treating microbe-mediated epithelial disorders
WO2005032462A2 (en) 2003-02-27 2005-04-14 Enzo Therapeutics, Inc. Glucocerebroside treatment of disease
US9717754B2 (en) 2003-02-27 2017-08-01 Enzo Therapeutics, Inc. Glucocerebroside treatment of disease
US20070184058A1 (en) * 2003-02-27 2007-08-09 Yaron Ilan Glucocerebroside treatment of pulmonary or respiratory diseases or disorders
US20050208083A1 (en) * 2003-06-04 2005-09-22 Nanobio Corporation Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof
US20050232981A1 (en) 2004-04-15 2005-10-20 Ben-Sasson Shmuel A Compositions capable of facilitating penetration across a biological barrier
CN101123982B (zh) * 2005-01-28 2015-06-17 西北大学 脂质和一氧化二氮组合作为用于增强疫苗功效的佐剂
EP1871349A1 (en) * 2005-04-11 2008-01-02 Nanobio Corporation Quaternary ammonium halides for treatment of infectious conditions
CA2618974C (en) * 2005-08-09 2014-01-28 Nanobio Corporation Nanoemulsion compositions having anti-inflammatory activity
US20080038295A1 (en) * 2006-04-13 2008-02-14 Regents Of The University Of Michigan Compositions and methods for orthopox virus vaccination
US10138279B2 (en) 2006-04-13 2018-11-27 Regents Of The University Of Michigan Compositions and methods for Bacillus anthracis vaccination
US9839685B2 (en) * 2006-04-13 2017-12-12 The Regents Of The University Of Michigan Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen
TW200824693A (en) * 2006-08-28 2008-06-16 Jazz Pharmaceuticals Inc Pharmaceutical compositions of clonazepam and methods of use thereof
EP2123296B1 (en) * 2007-01-31 2019-05-22 Hisamitsu Pharmaceutical Co., Inc. Adjuvant for transdermal or transmucosal administration and pharmaceutical preparation containing the same
WO2009014782A2 (en) * 2007-04-27 2009-01-29 Dow Global Technologies Inc. Improved production and in vivo assembly of soluble recombinant icosahedral virus-like particles
EP2293813A4 (en) 2008-05-23 2012-07-11 Univ Michigan NANOEMULSION VACCINES
BRPI0918652B1 (pt) 2008-09-17 2021-10-19 Chiasma, Inc. Composição farmacêutica compreendendo um meio hidrofóbico e uma forma sólida que compreende polipeptídeo e sal de ácido graxo de cadeia média, processo de produção da mesma e forma de dosagem oral
CN102596243B (zh) * 2009-06-16 2015-10-21 密执安大学评议会 纳米乳剂疫苗
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
DK2691530T3 (da) 2011-06-10 2018-05-22 Univ Oregon Health & Science Cmv-glycoproteiner og rekombinante vektorer
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
ES2744454T3 (es) 2013-10-31 2020-02-25 Hisamitsu Pharmaceutical Co Composición de adyuvante
US10525088B2 (en) 2014-05-30 2020-01-07 Kirin Holdings Kabushiki Kaisha Lactic acid bacterial immunopotentiating activity-increasing composition and method for increasing immunopotentiating activity of lactic acid bacteria
US10238709B2 (en) 2015-02-03 2019-03-26 Chiasma, Inc. Method of treating diseases
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
CN111721937B (zh) * 2019-03-29 2023-04-07 北京九强生物技术股份有限公司 人附睾蛋白4免疫比浊试剂盒
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1171125A (en) * 1966-06-08 1969-11-19 Glaxo Lab Ltd Improvements in or relating to Injectable Preparations
US4315925A (en) * 1980-05-30 1982-02-16 University Of Kentucky Research Foundation Method of administering natural female sex hormones
DE3446515A1 (de) * 1984-12-20 1986-06-26 Behringwerke Ag, 3550 Marburg Oeladjuvierte vaccine und verfahren zu ihrer herstellung
JPS61194034A (ja) * 1985-02-25 1986-08-28 Teijin Ltd 経鼻投与用粉末状組成物
JP2849632B2 (ja) * 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
NL9000207A (da) * 1990-01-29 1991-08-16 Duphar Int Res
GB9018690D0 (en) * 1990-08-24 1990-10-10 Wellcome Found Vaccines
WO1992018147A1 (en) * 1991-04-19 1992-10-29 Affinity Biotech, Inc. Convertible microemulsion formulations
CZ42894A3 (en) * 1991-08-26 1995-02-15 Scripps Research Inst Peptides inducing cytotoxic response of t lymphocytes to hepatitis b virus
CA2083553A1 (en) * 1991-11-25 1993-05-26 Kuniharu Seki Immunogen composition

Also Published As

Publication number Publication date
NO953182D0 (no) 1995-08-14
AU668290B2 (en) 1996-04-26
NO312057B1 (no) 2002-03-11
EP0682528B1 (en) 2000-08-02
ES2150982T3 (es) 2000-12-16
OA10564A (en) 2002-06-20
EP0682528A1 (en) 1995-11-22
JPH09508614A (ja) 1997-09-02
DK17093D0 (da) 1993-02-15
WO1994017827A1 (en) 1994-08-18
DE69425427T2 (de) 2001-02-08
ATE195077T1 (de) 2000-08-15
US5942237A (en) 1999-08-24
PT682528E (pt) 2001-01-31
AU6106594A (en) 1994-08-29
GR3034727T3 (en) 2001-01-31
DE69425427D1 (de) 2000-09-07
CA2156084A1 (en) 1994-08-18
NO953182L (no) 1995-10-12

Similar Documents

Publication Publication Date Title
DK0682528T3 (da) Lægemiddelpræparat til topisk administration af antigener og/eller vacciner til pattedyr via en slimhindemembran
KR950700758A (ko) 비-이온성 계면활성제 소포를 함유하는 백신(Vaccines containing non ionic surfactant vesicles)
DK0528859T3 (da) Oral vaccine, som omfatter antigen knyttet til overfladen af røde blodlegemer
ES8403024A1 (es) Un procedimiento para la fabricacion de un preparado farmaceutico para uso externo, a base de un compuesto no esteroi- dico.
DE69426077D1 (de) Adjuvantien für impfstoffe gegen das respiratorische synzitialvirus
PT2351579T (pt) Vacinas polipeptídicas para proteção ampla contra linhagens meningocócicas hipervirulentas
BR0107621A (pt) Sistema de liberação de droga por bombeamento osmótico/ difusão combinados
ES2117642T3 (es) Preparado farmaceutico que contiene n-glicofuroles y n-etilen glicoles.
YU28392A (sh) Vakcina koja sadrži glikoprotein d i 3deacilovani monofosforil lipid a
ES2125679T3 (es) Sistema transdermico de administracion simultanea de varios principios activos.
ATE50260T1 (de) Purinderivate, verfahren zu ihrer herstellung und pharmazeutische zubereitung.
DE69432790D1 (de) Auf papillomaviren basierende pharmazeutische präparate
FI972384A0 (fi) Uudet dipeptidiset p-amidinobentsyyliamidit, jotka sisältävät N-terminaalisia sulfonyyli- tai amidinosulfonyyliryhmiä
DK0692974T3 (da) Multikomponent clostridiumvacciner hvor saponin anvendes som adjuvans
Hancock et al. Serum neutralizing antibody titers of seropositive chimpanzees immunized with vaccines coformulated with natural fusion and attachment proteins of respiratory syncytial virus
FR2682114B1 (fr) Vaccin de sous-unite contre les infections a neisseria meningitidis et sous-unites correspondantes a l'etat purifie.
PT1144420E (pt) Fosfatidilinositois sulfatados a sua preparacao e a sua utilizacao
Sanchez et al. Immunological response to Vibrio cholerae O1 infection and an oral cholera vaccine among Peruvians
NO984782L (no) Nye indikasjoner for anvendelse som medikamenter av multipotente parapox immunitets induseringsmiddel fra attenuerte, ikke-immunogene poxviruser eller parapox viruser
MX9302272A (es) Retinoides solubles en agua.
DK0660825T3 (da) Antiinflammatoriske makrolactamer (cyclamenol)
NO943251L (no) Oral vaksine
De Sena et al. Epidemiological and clinic review of 2131 patients affected with an infection of oro-fecal transmission.